HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A

Cited by papers we hold 13

• Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T · 2023
  No notice
• Phenotypic signatures of immune selection in HIV-1 reservoir cells · 2023
  No notice
• Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial · 2022
  Corrected
• Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions · 2022
  No notice
• Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing · 2022
  No notice
• Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy · 2020
  No notice
• Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells · 2018
  No notice
• The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy · 2017
  No notice
• The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments · 2017
  No notice
• Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia · 2017
  No notice
• Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells · 2014
  No notice
• NK Cell Terminal Differentiation: Correlated Stepwise Decrease of NKG2A and Acquisition of KIRs · 2010
  No notice
• MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells · 2010
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.